Skip to main content
Premium Trial:

Request an Annual Quote

Lentigen and Dharmacon Pen shRNA Development Deal

NEW YORK (GenomeWeb News) – Lentigen and Dharmacon today said they plan to develop and manufacture lentiviral expression reagents to deliver short hairpin RNA expression vectors into cells using RNA interference-mediated gene silencing.
 
As part of the alliance Dharmacon will design reagents combined with Lentigen's high-titer LentiMax vector system to develop the lentiviral particles. Terms of the deal call for Lentigen to manufacture and Dharmacon to sell the resulting products.
 
Financial details were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.